TPST
Tempest Therapeutics·NASDAQ
--
--(--)
--
--(--)
TPST fundamentals
Tempest Therapeutics (TPST) released its earnings on Aug 11, 2025: revenue was 0 (YoY --), met estimates; EPS was -2.07 (YoY +62.09%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-2.07
+62.09%
Report date
Aug 11, 2025
Earnings Call
4:00 PM on Aug 11, 2025
Meeting link.EPS
Actual | -126.75 | -109.2 | -66.3 | -74.1 | -99.19 | -15.73 | -14.56 | -15.34 | -10.27 | -8.58 | -7.28 | -7.15 | -7.02 | -6.24 | -4.94 | -4.68 | -5.46 | -5.33 | -4.03 | -3.16 | -2.07 | ||||||||
Forecast | -130 | -106.6 | -89.7 | -66.3 | -11.375 | -13.6067 | -16.0333 | -14.5167 | -10.27 | -10.4325 | -9.8846 | -8.3525 | -6.7275 | -7.4497 | -5.0335 | -5.2332 | -5.2411 | -4.706 | -3.2742 | -3.2933 | -3.23 | ||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +2.50% | -2.44% | +26.09% | -11.76% | -772.00% | -15.60% | +9.19% | -5.67% | 0.00% | +17.76% | +26.35% | +14.40% | -4.35% | +16.24% | +1.86% | +10.57% | -4.18% | -13.26% | -23.08% | +4.05% | +35.91% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What guidance did Tempest Therapeutics's management provide for the next earnings period?What is Tempest Therapeutics's gross profit margin?What does Tempest Therapeutics do and what are its main business segments?What were the key takeaways from Tempest Therapeutics's earnings call?What is the revenue and EPS growth rate for Tempest Therapeutics year over year?What were the key takeaways from Tempest Therapeutics’s earnings call?What factors drove the changes in Tempest Therapeutics's revenue and profit?Did Tempest Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
